The heterogeneous acquisition of molecular alterations in patients treated with KRAS inhibitors was also highlighted in the biomarker analysis data from the CodeBreaK 100 trial194: at the time of progression following sotorasib monotherapy, 28% and 73% of NSCLC and CRC patients, respectively, acquired new molecular alterations, with RTK pathway alterations being the most common. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.